Schisandra — Research Profile

Schisandra is unique in containing all five flavors recognized in Traditional Chinese Medicine: sweet, sour, salty, bitter, and pungent. This is reflected in its Chinese name "wu wei zi." In TCM philosophy, this five-flavor profile means it acts on all five yin organs (liver, heart, spleen, lungs, kidneys), making it a comprehensive tonic. The sour flavor is most dominant, with a complex aftertaste.

Yes, schisandra has strong preclinical and emerging clinical evidence for liver protection. Schisandrin B enhances glutathione production, protects hepatocytes from toxin-induced damage, and may accelerate liver regeneration. In China and Russia, schisandra-based preparations have been used clinically for hepatitis and liver damage. It is one of the best-supported natural hepatoprotective agents after milk thistle.

Yes, schisandra and rhodiola are traditionally combined in adaptogenic formulas and were studied together (alongside eleuthero) in the ADAPT-232 formula. This combination showed cognitive and endurance benefits in clinical trials. The three adaptogens have complementary mechanisms and are generally considered safe to take together.

Controlled trials used standardized Schisandra chinensis fruit (berry) extracts at 0.5-1 g/day, and these are the forms with human efficacy and safety data behind them, unlike whole dried berries or tinctures that lack comparable trial support. No study has directly compared different forms head-to-head, so a lignan-standardized extract is the most evidence-aligned choice by default.

The strongest human evidence comes from 12-week randomized trials: about 1 g/day improved knee-extensor and quadriceps strength in older and postmenopausal adults, and 500 mg/day improved fasting and post-meal glucose in people with elevated blood sugar. A single dose of an adaptogen blend containing schisandra improved attention under stress. Widely cited liver-protective effects have so far been demonstrated only in animal studies, not in humans.

No standardized dose is established. In human randomized trials, 500 mg/day of Schisandra chinensis extract was used for glycemic outcomes, while roughly 1,000 mg/day was used for muscle-strength outcomes over 12 weeks. These extract doses are not interchangeable with whole-berry amounts.

Timing has not been directly compared in trials. The 12-week muscle-strength and blood-glucose studies reported only a total daily dose (500 mg to 1 g/day) and did not state a time of day or whether it was taken once or in divided doses, so no optimal timing is established for daily use. The one acute study used a single dose of an adaptogen blend about two hours before cognitive testing, which points toward daytime use if the goal is mental performance under stress.

In 12-week randomized trials at 500-1,000 mg/day of extract, no clinically significant adverse safety changes were reported, and the muscle-strength studies noted no significant adverse events. Systematic side-effect profiling at higher doses or beyond 12 weeks is lacking, so tolerability outside these tested ranges is genuinely uncertain rather than proven benign.

Yes, and this is its most important safety issue. Schisandra lignans inhibit CYP3A4 and P-glycoprotein: a Schisandra sphenanthera extract (Wuzhi) raised tacrolimus exposure sharply (Cmax +227%, AUC +164%) and allowed renal-transplant patients to cut their tacrolimus dose by about 34% while trough levels doubled. It can therefore raise blood levels of CYP3A4-substrate drugs such as immunosuppressants and midazolam, so anyone on narrow-therapeutic-index or transplant medications should not use it without medical supervision.

Human trial evidence is strongest for older or postmenopausal adults wanting muscle-strength support alongside light exercise, and for people with mildly elevated blood glucose; it has also been studied within adaptogen blends for stress-related mental fatigue. It is a poor fit for anyone taking CYP3A4-substrate drugs (especially immunosuppressants), who should avoid it unless a clinician is monitoring their medication levels.

Onset depends on the outcome. A single dose of an adaptogen blend containing schisandra (ADAPT-232) improved attention and mental speed about two hours after intake in stressed adults, though that was a multi-herb product rather than schisandra alone. For schisandra-specific outcomes such as muscle strength and blood-glucose control, controlled trials measured benefits over 12 weeks of daily use, so expect physical and metabolic effects to build over weeks rather than days.

The longest controlled human data run about 12 weeks. A 12-week trial of 500 mg/day Schisandra chinensis (Omija) extract in adults with elevated glucose reported no clinically significant changes in any safety parameter, and separate 12-week muscle-strength trials at roughly 1 g/day likewise recorded no significant adverse events. Safety beyond three months has not been established in controlled trials, so open-ended daily use is not backed by human data.

No tolerable upper intake level has been established for schisandra. Human trials used 500-1,000 mg/day of extract without clinically significant adverse safety changes over 12 weeks, but higher doses and long-term toxicity have not been characterized in controlled human studies. A specific concern is that schisandra lignans potently affect drug-metabolizing enzymes (CYP3A4 and P-glycoprotein), so taking more can meaningfully raise blood levels of certain co-administered medications.

Schisandra is most studied as part of adaptogen blends with Rhodiola rosea and Eleutherococcus (ADAPT-232/Chisan), which improved attention acutely and showed modest effects on fatigue and pain duration in a Long COVID trial. No specific supplement-supplement safety problem is documented, and the main interaction caution applies to prescription drugs rather than other supplements, because its lignans inhibit CYP3A4 and P-glycoprotein.

Human trials used defined Schisandra chinensis fruit extracts dosed 500-1,000 mg/day, so look for a product that names the species and standardizes to its lignans (such as schisandrin and schisandrin B). Note that northern Schisandra chinensis (wu wei zi) and southern Schisandra sphenanthera differ in lignan profile and enzyme-inhibiting potency, so the exact species and standardization on the label matter.